nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-4F97D685·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Neurology·Basis: Full text·Type: Cross-sectional study

Blood-based biomarker discovery in motor neuron disease using nucleic acid-linked immuno-sandwich assay.

Bozkurt et al.Bozkurt, Reid, Newton et al.·2026·Brain communications·10.1093/braincomms/fcag180 ↗

Primary claim

Neurofilament light and heavy chain, total tau (t-tau), phosphorylated tau (pTau)-181, pTau-217, pTau-231, fatty acid binding protein 3, amyloid beta (Aβ) 38 and Aβ40 levels were significantly elevated in MND (P < 0.05).

Supported · cross-sectional unadjusted comparisons limit disease specificity, especially for low-detectability pTau-217
In brief

Serum NULISAseq reproduces established MND biomarker signals and cross-platform correlations, but unadjusted demographic confounding limits disease-specific interpretation.

ReliabilityCaveats4 of 4 checks completeRead the entry ↓
Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

Motor neuron disease (MND) presents with phenotypic heterogeneity, is diagnostically challenging, and has poor prognosis. The absence of accessible blood-based biomarkers has hampered progress towards precision medicine. Highly sensitive immunoassays offer considerable promise for identifying blood-based biomarkers informing underlying pathophysiology and enabling accurate diagnosis and monitoring. We report findings on parallel use of the ultra-sensitive multiplexed NUcleic Acid-Linked Immuno-Sandwich Assay (NULISA) and single molecule array (Simoa), to interrogate serum from people with MND. Sera (48 MND, 38 controls) were analysed using a NULISAseq targeted neurodegenerative panel and a Simoa neurofilament light chain (NfL) and glial fibrillary acid protein (GFAP) duplex assay. Neurofilament light and heavy chain, total tau (t-tau), phosphorylated tau (pTau)-181, pTau-217, pTau-231, fatty acid binding protein 3, amyloid beta (Aβ) 38 and Aβ40 levels were significantly elevated in MND (P < 0.05). Simoa and NULISAseq assays demonstrated strong correlations for NfL and GFAP (r > 0.90). Use of the multiplexed NULISAseq panel confirmed a well-established NfL elevation in MND, and replicated findings for other proteins from recent studies. Results add confidence in the validity and reproducibility of biomarkers identified using NULISAseq, while offering insights into the underlying pathophysiology and heterogeneity of MND.

Key Claims

Primary finding · Supported

Neurofilament light and heavy chain, total tau (t-tau), phosphorylated tau (pTau)-181, pTau-217, pTau-231, fatty acid binding protein 3, amyloid beta (Aβ) 38 and Aβ40 levels were significantly elevated in MND (P < 0.05).

Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

cross-sectional unadjusted comparisons limit disease specificity, especially for low-detectability pTau-217

Abstract; Results, Fig. 2A
Quote verified
Secondary · Well-supported

Simoa and NULISAseq assays demonstrated strong correlations for NfL and GFAP (r > 0.90).

reported Spearman correlations directly support the claim for both measured analytes

Abstract; Results, Fig. 3A–B
Quote verified
Secondary · Tentative

Results add confidence in the validity and reproducibility of biomarkers identified using NULISAseq.

two-analyte cross-platform correlation cannot establish broader biomarker validity or reproducibility

Abstract; Conclusion
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Orthogonal comparison with established Simoa assays

NULISAseq and Simoa measurements were strongly correlated for NfL and GFAP, providing direct cross-platform evidence for those two analytes.

↳ Results, Fig. 3A–B

#methodological rigour

Defined assay quality-control procedures

The workflow reports a randomized plate map, internal-control acceptance ranges, detectability thresholds, duplicate Simoa measurements, and a CV criterion.

↳ Methods, NULISAseq Profiling and Simoa sections

#positioning

Direct engagement with recent literature

The discussion compares the serum findings with recent plasma and genetic-ALS NULISAseq studies and delineates the serum and broader-MND extensions.

↳ Discussion, paragraphs 2–4

Limitations

#methodological rigour

Primary comparisons lack confounding adjustment

Age and sex differed between disease and control groups, but biomarker comparisons used unadjusted independent t-tests without matching, regression, stratification, or sensitivity analysis.

↳ Methods, Statistical Analysis; Results, paragraphs 1–2; Discussion, limitations paragraph

#methodological rigour

Selected-sample analyses overstate discrimination

Clustering and ROC analyses were conducted in the discovery sample using the nine proteins selected as significant, without cross-validation or independent validation. This limits claims of clear separation, heterogeneity, and diagnostic performance.

↳ Results, Fig. 2B and Supplementary Fig. 9; Discussion, heatmap-analysis paragraph

#reporting

Conclusions exceed the pilot evidence

The Conclusion invokes astrocytic degeneration, pathophysiological insight, and assay robustness although GFAP was unchanged and the study was a small, unadjusted cross-sectional pilot.

↳ Discussion, neuroinflammation and limitations paragraphs; Conclusion

Does this match your read? Add your assessment ↓

Nabu Commentary

The serum panel identified nine FDR-significant proteins and reproduced the established NfL signal, while Fig. 3 provides direct cross-platform correlation evidence for NfL and GFAP. Methodological credit is limited by unadjusted t-tests despite documented age and sex differences between groups. The selected-feature clustering and in-sample ROC analysis do not independently establish diagnostic separation or MND heterogeneity. The paper is therefore best interpreted as an exploratory replication and assay-concordance study rather than clinical validation of a disease-specific panel.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.8±0.2

Contribution
3.2

The study adds an incremental serum-based replication across a mixed MND cohort and a two-analyte comparison with Simoa. Its advance remains limited because NfL elevation is established and several panel findings overlap recent NULISAseq studies.

Abstract; Discussion, paragraphs 2–4

Use of the multiplexed NULISAseq panel confirmed a well-established NfL elevation in MND

Methodological Rigour
2.4

Randomized plate allocation, assay QC, FDR correction, and duplicate Simoa measurements support the laboratory workflow. The primary comparisons remain unadjusted for documented age and sex differences, while control selection and in-sample feature evaluation add uncertainty.

Methods, NULISAseq Profiling and Statistical Analysis; Results, paragraphs 1–2 and Fig. 2

These exclusions affected the sex distribution difference between groups for the final analysis

Reporting
3.3

The manuscript follows a clear progression from hypotheses through multiplex testing and cross-platform comparison. Central claims about assay robustness, astrocytic degeneration, and heterogeneity are stronger than the unadjusted pilot and selected-feature clustering support.

Abstract; Discussion, heatmap-analysis paragraph; Conclusion

provide further confidence in the validity and robustness of the NULISAseq assay

Positioning
3.0

The discussion compares the findings with recent NULISAseq and broader biomarker studies and identifies the serum and mixed-MND extensions. Age and sex imbalance is acknowledged but not traced through the certainty of disease-specific biomarker interpretations.

Discussion, paragraphs 2–4 and limitations paragraph; Conclusion

differences between the age and sex of disease and control groups

Reliability

Caveats4 of 4 checks


Results checkNoted

One reported value does not reconcile, but the key claims do not rest on it.

Reporting and transparencyClean

No reporting or research-conduct concern was raised that warrants a grounded finding.

Ethics approval: declared · Preregistration: not stated · Data availability: declared · Code availability: declared

Reference IntegrityClean

33 references in manuscript 33 of 33 checkable references found in an index

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Motor neuron disease
Type of advanceEmpirical
Route to useSuggested
AdvanceConsolidates
BeneficiariesSmall
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessFoundational
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The primary claim rests on a single cross-sectional observational pilot cohort of 48 MND cases and 38 controls with no independent replication or validation of the biomarker elevations.

From the paper
“pTau may therefore be a helpful biomarker reflecting distinct pathology, and of utility for disease monitoring including in clinical trials.”

The paper names possible real-world uses of the biomarker findings, diagnosis and disease monitoring, but does not specify who would act on them or in what concrete decision setting.

Pathway

Neurologists and clinical trial teams could adopt validated blood-based biomarkers such as NfL and pTau to support MND diagnosis, subtyping and disease monitoring.

Barrier

The modest single-cohort cross-sectional design requires replication in larger, well-characterized longitudinal cohorts before these biomarkers can enter clinical use.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca2+-permeable AMPA receptor-mediated excitotoxicity

    Selvaraj, Livesey, Zhao, et al. · 2018 · Basic medicine

    Primary claim

    increased expression of GluA1 AMPA receptor (AMPAR) subunit occurs in MNs with C9ORF72 mutations that leads to increased Ca2+-permeable AMPAR expression and results in enhanced selective MN vulnerability to excitotoxicity.

    Tentative
    Evidence Score
    3.1±0.2
    Reliability
    Caveats
  2. Astrocytes regulate axonal mitochondrial transport deficits in C9ORF72 amyotrophic lateral sclerosis motor neurons

    Stavrou, Heffernan, Carter, et al. · 2026 · Basic medicine

    Primary claim

    human-induced pluripotent stem-cell-derived astrocytes carrying the C9ORF72 mutation disrupt mitochondrial axonal transport and mitochondrial function in cocultured motor neurons (MNs)

    Supported
    Evidence Score
    3.1±0.1
    Reliability
    Caveats
  3. Alzheimer's Disease Co-Pathology and Cognitive Impairment in Amyotrophic Lateral Sclerosis

    Kasper, Lehto, Jürs, et al. · 2026 · Clinical medicine

    Primary claim

    CSF p-tau and total-tau levels were strongly associated with domain-specific cognitive performance.

    Tentative
    Evidence Score
    3.2±0.2
    Reliability
    Concerns

How the rubric works →